Last reviewed · How we verify
Separate administration
This refers to a vaccination strategy where multiple vaccine components are administered at separate timepoints rather than as a combined formulation.
This refers to a vaccination strategy where multiple vaccine components are administered at separate timepoints rather than as a combined formulation. Used for Vaccination strategy under investigation in Phase 3 trials by Sanofi Pasteur.
At a glance
| Generic name | Separate administration |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Separate administration of vaccine components allows for individualized dosing schedules and may optimize immune responses by spacing antigenic exposures. This approach is commonly used in multi-component vaccine regimens to manage reactogenicity and enhance immunogenicity of specific vaccine components.
Approved indications
- Vaccination strategy under investigation in Phase 3 trials by Sanofi Pasteur
Common side effects
Key clinical trials
- Accelerated TMS for Apathy in PD (NA)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- The Impact of Music Medicine on Preterm Brain Development and Behavior (NA)
- Effectiveness of Osteopathy as an Adjunct to Optometric Vision Therapy in Vergence Disorders (NA)
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Antithrombotic Activities of Sotagliflozin vs. Empagliflozin (PHASE4)
- A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Separate administration CI brief — competitive landscape report
- Separate administration updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI